{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:42:25Z","timestamp":1790106145935,"version":"4.0.1"},"reference-count":98,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2686291","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:08:21Z","timestamp":1780722501000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Accelerating\n                    <i>Shigella<\/i>\n                    vaccines: from decades of research to global access"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8075-5018","authenticated-orcid":false,"given":"Shiferaw Tesfaye","family":"Tilahun","sequence":"first","affiliation":[{"name":"International Vaccine Institute","place":["Seoul, South Korea"]},{"name":"Ethiopian Public Health Institute","place":["Addis Ababa, Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-1144","authenticated-orcid":false,"given":"Sun Bean","family":"Kim","sequence":"additional","affiliation":[{"name":"International Vaccine Institute","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-9322","authenticated-orcid":false,"given":"Naveena Aloysia","family":"D\u2019Cor","sequence":"additional","affiliation":[{"name":"International Vaccine Institute","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1981-7366","authenticated-orcid":false,"given":"Jessica","family":"Cowden","sequence":"additional","affiliation":[{"name":"International Vaccine Institute","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7021","authenticated-orcid":false,"given":"Tarun","family":"Saluja","sequence":"additional","affiliation":[{"name":"International Vaccine Institute","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"5","key":"e_1_3_6_3_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(24)00691-1","article-title":"Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990\u20132021, for 204 countries and territories: a systematic analysis for the global burden of disease study 2021","volume":"25","author":"GBD 2021 Diarrhoeal Diseases Collaborators","year":"2025","unstructured":"GBD 2021 Diarrhoeal Diseases Collaborators. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990\u20132021, for 204 countries and territories: a systematic analysis for the global burden of disease study 2021. Lancet Infect Dis. 2025;25(5):519\u201316.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"e_1_3_6_4_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000475","article-title":"Recent insights into Shigella: a major contributor to the global diarrhoeal disease burden","volume":"31","author":"Baker S.","year":"2018","unstructured":"Baker S. Recent insights into Shigella: a major contributor to the global diarrhoeal disease burden. Curr Opin Infect Dis. 2018;31(5):449\u2013454.","journal-title":"Curr Opin Infect Dis"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30045-7"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084329"},{"key":"e_1_3_6_7_1","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Geneva: World Health Organization; 2017 [cited 2026 Mar 21]. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s219755"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054649"},{"issue":"2","key":"e_1_3_6_10_1","first-page":"133","article-title":"Shigellosis","volume":"43","author":"Niyogi SK","year":"2005","unstructured":"Niyogi SK. Shigellosis. J Microbiol. 2005;43(2):133\u2013143.","journal-title":"J Microbiol"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01033-5"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.03.003"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011475"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003708"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac132"},{"key":"e_1_3_6_16_1","volume-title":"StatPearls [Internet]","author":"Samandari T","year":"2025","unstructured":"Samandari T, Okafor CN. Shigellosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Mar 21]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482337\/"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30392-3"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50546"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12081677"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279012"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-056002"},{"key":"e_1_3_6_22_1","unstructured":"Centers for Disease Control and Prevention. Increase in extensively drug-resistant shigellosis in the United States [Internet]. Atlanta (GA): CDC; 2023 [cited 2026 Mar 21]. Available from: https:\/\/www.cdc.gov\/han\/2023\/han00486.html"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009826"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.bai-0023-2019"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08970"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1520699113"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(02)00689-9"},{"issue":"19","key":"e_1_3_6_28_1","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1093\/nar\/gki954","article-title":"Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery","volume":"33","author":"Yang F","year":"2005","unstructured":"Yang F, Yang J, Zhang X, et al. Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res. 2005;33(19):6445\u20136458.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.2.386-389.1991"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00064"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/aem.01175-25"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008326"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040418"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671325"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116134"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90094-3"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00102-7"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050675"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268814000260"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1606971"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.050"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.10.011"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00146-18"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1439-1"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059465"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1086\/313437"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00122-21"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091376"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00421-7"},{"key":"e_1_3_6_50_1","unstructured":"World Health Organization. WHO preferred product characteristics for vaccines against Shigella [Internet]. Geneva: World Health Organization; 2021 [cited 2026 Mar 21]. Available from: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b7b0218c-96b5-4baf-945d-2ff2c0f81576\/content"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228148"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.11.001"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.06.063"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020340"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00019-23"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1483740"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00224-16"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103310"},{"key":"e_1_3_6_59_1","unstructured":"Valneva. Valneva and LimmaTech awarded FDA Fast Track designation for tetravalent Shigella vaccine candidate S4V [Internet]. Saint-Herblain: Valneva; 2024 [cited 2026 Mar 21]. Available from: https:\/\/valneva.com\/press-release\/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella-vaccine-candidate-s4v\/"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010033"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.06.052"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126263"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30488-6"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00624-y"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030403"},{"issue":"1","key":"e_1_3_6_66_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofad586","article-title":"Optimizing vaccine trials for enteric diseases: the Enterics for Global Health (EFGH) Shigella surveillance study","volume":"11","author":"Vannice K","year":"2024","unstructured":"Vannice K, MacLennan CA, Long J, et al. Optimizing vaccine trials for enteric diseases: the Enterics for Global Health (EFGH) Shigella surveillance study. Open Forum Infect Dis. 2024;11(Suppl 1):S1\u2013S5.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1652460"},{"key":"e_1_3_6_68_1","unstructured":"GSK. GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development [Internet]. London: GSK; 2024 [cited 2026 Mar 21]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech-for-continued-development\/"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040548"},{"key":"e_1_3_6_70_1","volume-title":"Paper presented at: Vaccines Against Shigella and ETEC (VASE) Virtual Symposium","author":"Clarkson K","year":"2021","unstructured":"Clarkson K, Gutierrez R, Turbyfill K, et al. Clinical evaluation of Shigella flexneri 2a detoxified artificial invaplex. Paper presented at: Vaccines Against Shigella and ETEC (VASE) Virtual Symposium; Washington, DC, USA. 2021 Nov 28\u201330."},{"issue":"1","key":"e_1_3_6_71_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/vaccines13010048","article-title":"Safety, tolerability, and immunogenicity of the invaplexAR-detox Shigella vaccine co-administered with the dmLT adjuvant in Dutch and Zambian adults: study protocol for a multi-center, randomized, double-blind, placebo-controlled, dose-escalation Phase Ia\/b clinical trial","volume":"13","author":"Roozen GV","year":"2025","unstructured":"Roozen GV, Sukwa N, Chirwa M, et al. Safety, tolerability, and immunogenicity of the invaplexAR-detox Shigella vaccine co-administered with the dmLT adjuvant in Dutch and Zambian adults: study protocol for a multi-center, randomized, double-blind, placebo-controlled, dose-escalation Phase Ia\/b clinical trial. Vaccines (Basel). 2025;13(1):48.","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_6_72_1","unstructured":"Indian Council of Medical Research. ICMR distributes a license for Shigella vaccine [Internet]. New Delhi: ICMR; 2019 [cited 2026 Mar 21]. Available from: https:\/\/www.icmr.gov.in\/post\/icmr-distributes-a-license-for-shigella-vaccine-april-2019"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01064-6"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632117"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00260-18"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00555-25"},{"key":"e_1_3_6_77_1","unstructured":"World Health Organization. WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research development and strategies to prevent and control antimicrobial resistance [Internet]. Geneva: World Health Organization; 2024 [cited 2026 Mar 21]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00906-1"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab462"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33296-8"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111168"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.201237"},{"key":"e_1_3_6_83_1","unstructured":"World Health Organization. Vaccines eligible for WHO prequalification [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Mar 21]. Available from: https:\/\/extranet.who.int\/prequal\/vaccines\/prequalified-vaccines"},{"key":"e_1_3_6_84_1","unstructured":"Gavi the Vaccine Alliance. Vaccine investment strategy 2024 [Internet]. Geneva: Gavi the Vaccine Alliance; 2024 [cited 2026 Mar 21]. Available from: https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy"},{"key":"e_1_3_6_85_1","unstructured":"Gavi Board. Annex B \u2013 summary of recommendations and costs [Internet]. Geneva: Gavi the Vaccine Alliance; 2024 [cited 2026 Mar 21]. Available from: https:\/\/www.gavi.org\/sites\/default\/files\/board\/minutes\/2024\/6-7-june10%20-%20Annex%20B%20-%20Summary%20of%20recommendations%20and%20costs.pdf"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00112-5"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101076"},{"key":"e_1_3_6_88_1","doi-asserted-by":"crossref","unstructured":"Kaminski RW Pavlinac PB Platts-Mills JA et al. WHO workshop report: regulatory science to inform clinical pathways for Shigella vaccines intended for use in children in low-and middle-income countries. MDPI; 2025.","DOI":"10.3390\/vaccines13050439"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60844-2"},{"key":"e_1_3_6_90_1","unstructured":"Gallant RM Savarino P Pulido S et al. Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design. bioRxiv [Preprint]. 2025 [cited 2026 Mar 21]. doi: 10.1101\/2025.12.16.694763"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426211122"},{"key":"e_1_3_6_92_1","first-page":"79","volume-title":"The World Health Organization prequalification programme\u2014playing an essential role in assuring quality medical products","author":"Coyne PE","year":"2019","unstructured":"Coyne PE. The World Health Organization prequalification programme\u2014playing an essential role in assuring quality medical products. Oxford University Press; 2019. p. 79\u201380."},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.066"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.02.073"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00192-4"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.11.045"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100368"},{"key":"e_1_3_6_98_1","volume-title":"ASVAC2022: 8th Asian vaccine conference","author":"Galagoda GC","year":"2023","unstructured":"Galagoda GC, Perera J, de Silva R, et al. ASVAC2022: 8th Asian vaccine conference. London, UK: Taylor & Francis; 2023."},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313310"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00446-5"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2686291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:13:59Z","timestamp":1781183639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2686291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2686291"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2686291","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2686291"}}